Skip to main content

Table 3 Pathology comparison of of multiple primary lung adenocarcinomas in different EGFR and ALK status (in pre-lesions)

From: CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas

Variable EGFR+ (n = 62) EGFR- (n = 73) Total P ALK+ (n = 23) ALK-(n = 112) Total P
TNM stagea     0.312     0.160
 I-II 22(35) 20(27) 42(31)   10(43) 32(29) 42(31)  
 III-IV 40(65) 53(73) 93(29)   13(57) 80(71) 93(68)  
Histological subtype
 Lepidic predominantb 15(24) 10(14) 25(19) 0.118 3(13) 22(20) 25(19) 0.567
 other subtype1c 47(76) 63(86) 110(81)   20(87) 90(80) 110(81)  
  Solid or Mucinous 5(8) 11(15) 16(12) 0.210 8(35) 8(7) 16(12) <0.001*
 other subtype 2d 57(92) 61(84) 118(88)   15(65) 103(93) 118(88)  
  Acinar 30(48) 29(40) 59(43)   7(30) 53(47) 59(44)  
  Papillary 8(13) 21(29) 29(21)   5(22) 24(21) 29(21)  
  Solid 3(5) 8(11) 11(8)   6(26) 5(4) 11(8)  
  Mucinous 1(2) 3(4) 4(3)   2(9) 2(2) 4(3)  
  Micropapillary 1(2) 2(3) 3(2)   2(9) 1(1) 3(2)  
  Sieve 2(3) 2(3) 4(3)   0(0) 4(3) 4(3)  
 Pleural invasion 25(40) 27(37) 52(39) 0.691 9(39) 41(37) 52(39) 0.819
  1. * P values were based on comparisons between the two groups
  2. a TNM staging was based on the IASLC 8th TNM Lung Cancer Staging System
  3. b Lepidic predominant includes: adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant invasive adenocarcinoma
  4. c Other subtypes1 include: acinar, papillary, micropapillary, and solid predominant adenocarcinoma, as well as variants of invasive adenocarcinoma
  5. d Other subtypes2 include: adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic, , acinar, papillary, micropapillary, and sieve predominant adenocarcinoma
  6. EGFR epidermal growth factor receptor, ALK anaplastic large-cell lymphoma kinase, EGFR + EGFR mutation, EGFR- EGFR wild type mutation, ALK + ALK positive, ALK- ALK negative